Andrx Expands Business Development Effort; Jeffrey Long-McGie Joins as VP Business Development.

FORT LAUDERDALE, Fla. -- Andrx Corporation (Nasdaq:ADRX) today announced that Jeffrey Long-McGie has joined Andrx Pharmaceuticals, Inc. ("Andrx Pharma") as a Vice President of Business Development, responsible for acquisitions, product licensing and building domestic alliances. Mr. Long-McGie is a former specialty pharmaceutical analyst with ThinkEquity Partners. Mr. Long-McGie will work together with Andrx Pharma President, Larry Rosenthal, and Andrx Pharma Vice President, Habib Nasirullah, who will assume responsibility for the Company's international business development opportunities, particularly in the areas of manufacturing, raw material sourcing and development alliances.

Mr. Rosenthal said, "We are excited to have Jeffrey and Habib, two very knowledgeable individuals, join our business development efforts. Together, our industry contacts will enhance Andrx's ability to expand this aspect of our business and increase shareholder value."

About Andrx Corporation:

We are a pharmaceutical company that develops, manufactures and commercializes generic versions of controlled-release, niche and immediate-release pharmaceutical products, including oral contraceptives. We also distribute pharmaceuticals, primarily generics, which have been commercialized by others, as well as our own, primarily to independent pharmacies, pharmacy chains, pharmacy buying groups and physicians' offices.

Forward-looking statements (statements which are not historical facts) in this release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained herein or which are otherwise made by or on behalf of the Company that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "to," "plan," "expect," "believe," "anticipate," "intend," "could," "would," "estimate," or "continue" or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Investors are cautioned that all forward-looking statements involve risk and uncertainties, including but not limited to, the Company's dependence on a relatively small number of products, licensing revenues, the timing and outcome of litigation and future product launches, government regulation, competition, manufacturing capacities, safety issues, output and quality processes. Andrx Corporation is also subject to other risks detailed herein or detailed from time to time in its filings with the U.S. Securities and Exchange Commission. Andrx disclaims any responsibility to update the statements contained herein.

This release and additional information about Andrx Corporation is also available on the Internet at: http://www.andrx.com.